Skip to main content
. 2018 Jun;9(3):404–415. doi: 10.21037/jgo.2018.01.09

Figure 5.

Figure 5

In MSI-H or POLE-mutated metastatic colorectal tumors, levels of CD4 (A, P=0.39) and percentage of CD4+ FOXP3+ T-cells (B, P=0.68) were not significantly different in pretreatment tumor specimens of responders to PD-1/PD-L1/CTLA-4 blockade and nonresponders, but (C) the percentage of CD4+ Tbet+ T-cells was significantly higher in responders compared to nonresponders (P=0.0007). MSI-H, microsatellite instability-high; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T lymphocyte-associated protein 4.